Investors will be keen to see what strategic goals the newly independent pharmaceutical group Indivior (INDV) publishes alongside its inaugural set of results next week. Not much is known about the entity spun out of consumer goods giant Reckitt Benckiser (RB.) in December.
Indivior can trace its roots back to 1994, when RB established the Buprenorphine Business Group to focus on developing buprenorphine for patients addicted to opioids. Twenty years later, the group's leading addiction-control product, Suboxone, is still based on that compound.
But the company faces an uphill battle to protect its franchise. Suboxone has lost its patent protection and, previously, revenues from the product accounted for almost the entire business. Prior to the demerger, analysts expected revenues to decline by roughly 12.5 per cent to £680m this year as a result.
